Triple

T1169406
Position Surface form Disambiguated ID Type / Status
Subject Spinraza E24879 entity
Predicate hasActiveIngredient P12771 FINISHED
Object nusinersen
Nusinersen is an antisense oligonucleotide drug used to treat spinal muscular atrophy by increasing production of functional survival motor neuron (SMN) protein.
 E24879 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nusinersen | Statement: [Spinraza, hasActiveIngredient, nusinersen]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: nusinersen
Context triple: [Spinraza, hasActiveIngredient, nusinersen]
  • A. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • B. onasemnogene abeparvovec
    Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
  • C. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • D. SMN2
    SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
  • E. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: nusinersen
Triple: [Spinraza, hasActiveIngredient, nusinersen]
Generated description
Nusinersen is an antisense oligonucleotide drug used to treat spinal muscular atrophy by increasing production of functional survival motor neuron (SMN) protein.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: nusinersen
Target entity description: Nusinersen is an antisense oligonucleotide drug used to treat spinal muscular atrophy by increasing production of functional survival motor neuron (SMN) protein.
  • A. Spinraza chosen
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • B. onasemnogene abeparvovec
    Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
  • C. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • D. SMN2
    SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
  • E. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac7645abc8819086de42185bd403ed completed March 7, 2026, 7:02 p.m.
NEDg Description generation batch_69ac76f20f308190be3c831eb2d59763 completed March 7, 2026, 7:05 p.m.
NED2 Entity disambiguation (via description) batch_69ac77585c708190b5f4b239d9574cd7 completed March 7, 2026, 7:07 p.m.
Created at: March 1, 2026, 7:45 p.m.